NCT00081172View on ClinicalTrials.gov

Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the Prostate

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

January 31, 2004

Study Completion Date

May 31, 2006

Conditions
Prostate Cancer
Interventions
RADIATION

lutetium Lu 177 monoclonal antibody J591

Trial Locations (3)

10021

Memorial Sloan-Kettering Cancer Center, New York

New York Weill Cornell Cancer Center at Cornell University, New York

10032

Herbert Irving Comprehensive Cancer Center at Columbia University, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00081172 - Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the Prostate | Biotech Hunter | Biotech Hunter